Literature DB >> 29754785

Prognostic factors including lymphovascular invasion on survival for resected non-small cell lung cancer.

Lawrence Okiror1, Leanne Harling1, Levon Toufektzian1, Juliet King1, Tom Routledge1, Karen Harrison-Phipps1, John Pilling1, Lukacs Veres1, Ruchi Lal1, Andrea Bille2.   

Abstract

OBJECTIVES: The aim of this study was to report on the influence of tumor lymphovascular invasion on overall survival and in patients with resected non-small cell lung cancer and identify prognostic factors for survival.
METHODS: This is a retrospective observational study of a consecutive series of patients who had surgical resection of non-small cell lung cancer in a single institution. The study covers a 3-year period. Overall survival was estimated by Kaplan-Meier method and multivariate Cox regression analysis was used to evaluate the relationship of lymphovascular invasion and other clinicopathologic variables. A multivariate regression was used to assess the relationship between tumor lymphovascular invasion and other clinical and pathologic characteristics.
RESULTS: A total of 524 patients were identified and included in the study. Two hundred twenty-five patients (43%) had tumors with lymphovascular invasion. Patients with tumor lymphovascular invasion had a lower overall survival (P < .0001). Tumor lymphovascular invasion was independently associated with visceral pleural involvement (P < .0001). In a multivariable model, lymphovascular invasion (hazard ratio [HR], 2.58; 95% confidence interval [CI], 1.63-4.09; P < .0001), parietal pleural invasion (HR, 45.4; 95% CI, 2.08-990; P = .015), advanced age (HR, 1.028; 95% CI, 1.009-1.048; P = .004), and N2 lymph node involvement (HR, 1.837; 95% CI, 1.257-2.690; P = .002) were independent prognostic factors for lower overall survival.
CONCLUSIONS: Lymphovascular invasion is associated with a worse overall survival in patients with resected non-small cell lung cancer regardless of tumor stage. Parietal pleural involvement, N2 nodal disease, and advanced age independently predict poor overall survival.
Copyright © 2018 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  lymphovascular invasion; non–small cell lung cancer; overall survival

Mesh:

Year:  2018        PMID: 29754785     DOI: 10.1016/j.jtcvs.2018.02.108

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  10 in total

1.  Computed tomography-based radiomics analysis to predict lymphovascular invasion in esophageal squamous cell carcinoma.

Authors:  Hui Peng; Qiuxing Yang; Ting Xue; Qiaoling Chen; Manman Li; Shaofeng Duan; Bo Cai; Feng Feng
Journal:  Br J Radiol       Date:  2021-12-15       Impact factor: 3.039

2.  Molecular, clinicopathological characteristics and surgical results of resectable SMARCA4-deficient thoracic tumors.

Authors:  Haohua Teng; Chunyu Ji; Jizhuang Luo; Bowen Ding; Alessio Campisi; Tangbing Chen
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-19       Impact factor: 4.322

3.  Impact of microvascular invasion on 5-year overall survival of resected non-small cell lung cancer.

Authors:  Andreia Salarini Monteiro; Sérgio Ricardo de Carvalho Araújo; Luiz Henrique Araujo; Mirian Carvalho de Souza
Journal:  J Bras Pneumol       Date:  2022-07-08       Impact factor: 2.800

4.  Biomarker Potential of Preoperative Tumor Size in Determination of the Lymphovascular Invasion in Squamous Cell Lung Cancer and Lung Adenocarcinoma.

Authors:  Kemal Grbic; Aida Mujakovic; Orhan Lepara; Zahid Lepara; Edin Begic; Ferid Krupic
Journal:  Int J Appl Basic Med Res       Date:  2021-04-08

5.  Clinicopathological predictors of survival in resected primary lung adenocarcinoma.

Authors:  Hiral Jhala; Leanne Harling; Alberto Rodrigo; Daisuke Nonaka; Emma Mclean; Wen Ng; Lawrence Okiror; Andrea Bille
Journal:  J Clin Pathol       Date:  2021-04-07       Impact factor: 4.463

6.  Lymph but Not Blood Vessel Invasion Is Independent Prognostic in Lung Cancer Patients Treated by VATS-Lobectomy and Might Represent a Future Upstaging Factor for Early Stages.

Authors:  Melanie Biesinger; Nele Eicken; Alexander Varga; Michael Weber; Milos Brndiar; Georg Erd; Peter Errhalt; Klaus Hackner; Sarah Hintermair; Alexander Petter-Puchner; Axel Scheed; Elisabeth Stubenberger; Bahil Ghanim
Journal:  Cancers (Basel)       Date:  2022-04-08       Impact factor: 6.575

7.  Lymphovascular invasion: A non-sized T descriptor for stage IA non-small cell lung cancer.

Authors:  Jing-Sheng Cai; Xun Wang; Fei Yang; Yun Li; Man-Tang Qiu
Journal:  Thorac Cancer       Date:  2022-06-07       Impact factor: 3.223

8.  Survival Rates of Patients with Non-Small Cell Lung Cancer Depending on Lymph Node Metastasis: A Focus on Saliva.

Authors:  Lyudmila V Bel'skaya; Elena A Sarf; Victor K Kosenok
Journal:  Diagnostics (Basel)       Date:  2021-05-20

9.  Biochemical Markers of Saliva in Lung Cancer: Diagnostic and Prognostic Perspectives.

Authors:  Lyudmila V Bel'skaya; Elena A Sarf; Victor K Kosenok; Ivan A Gundyrev
Journal:  Diagnostics (Basel)       Date:  2020-03-27

10.  [Prognostic Factors of N2 Stage Non-small Cell Lung Cancer after Surgery].

Authors:  Zhenyu Yang; Shiyou Wei; Liang Xia; Lunxu Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-01-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.